Search

Your search keyword '"Albertelli M."' showing total 188 results
Start Over Author "Albertelli M."
188 results on '"Albertelli M."'

4. Comparison of two approaches for the direct optimisation of a car engine intake port

Author

Maisonneuve J. J., Pécot F., Pagès A., Albertelli M., and Visconti J.

Subjects
Industrial engineering. Management engineering, T55.4-60.8, Industrial directories, T11.95-12.5
Abstract

The shape optimisation involving complex flows, and based on direct CFD approaches, has now become very possible within industrial contexts, thanks to recent advances in optimal design technologies. However, one key remaining issue is related with the way the shape deformations are modelled. This paper presents the development of such an optimisation procedure, applied to a car engine air intake port, and compares two alternative methods for the shape deformation modelling. Global port variations are defined through a set of shape parameters. The first option consists in building a CAD model (Catia v5) to allow deformations, followed by a grid generation stage with tools enabling to generate and adapt the mesh to shape variations (Gridgen). The second option consists in starting from a grid done for a given shape, and defining parametric deformations on this grid, with a morphing tool (Sculptor). Then, after both modelling methods, the flow calculation is carried out with a CFD solver (Fluent). The resulting fields are processed by a flow post-processor (Fieldview) and by a Matlab procedure to extract the global criteria involved as optimisation objectives: the flow rate and the tumble. All this process is bundled within the modeFRONTIER multi-objective design environment. Similar optimisation approaches were led on both cases, involving mixed response surfaces – direct calculation evaluations of the designs, and a multi-objective genetic algorithm. The paper presents the main results, highlights the advantages and shortcomings of both modelling methods, and provides guidelines for their use and improvements, in view of practical industrial applications.

Published
2008
Full Text
View/download PDF

5. Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study

Author

Ruggeri, R. M., Altieri, B., Razzore, P., Retta, F., Sperti, E., Scotto, G., Brizzi, M. P., Zumstein, L., Pia, A., Lania, A., Lavezzi, E., Nappo, G., Laffi, A., Albertelli, M., Boschetti, M., Hasballa, I., Veresani, A., Prinzi, N., Pusceddu, S., Oldani, S., Nichetti, F., Modica, R., Minotta, R., Liccardi, A., Cannavale, G., Grossrubatscher, E. M., Tarsitano, M. G., Zamponi, V., Zatelli, M. C., Zanata, I., Mazzilli, R., Appetecchia, M., Davì, M. V., Guarnotta, V., Giannetta, E., La Salvia, A., Fanciulli, G., Malandrino, P., Isidori, A. M., Colao, A., and Faggiano, A.

Published
2024
Full Text
View/download PDF

8. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)

Author

Green, Jennifer B., Everett, Brendan M., Ghosh, Alokananda, Younes, Naji, Krause-Steinrauf, Heidi, Barzilay, Joshua, Desouza, Cyrus, Inzucchi, Silvio E., Pokharel, Yashashwi, Schade, David, Scrymgeour, Alexandra, Tan, Meng H., Utzschneider, Kristina M., Mudaliar, Sunder, Crandall, J.P., McKee, M.D., Behringer-Massera, S., Brown-Friday, J., Xhori, E., Ballentine-Cargill, K., Duran, S., Estrella, H., Gonzalez de la Torre, S., Lukin, J., Phillips, L.S., Burgess, E., Olson, D., Rhee, M., Wilson, P., Raines, T.S., Boers, J., Costello, J., Maher-Albertelli, M., Mungara, R., Savoye, L., White, C.A., Gullett, C., Holloway, L., Morehead, F., Person, S., Sibymon, M., Tanukonda, S., Adams, C., Ross, A., Balasubramanyam, A., Gaba, R., Gonzalez Hattery, E., Ideozu, A., Jimenez, J., Montes, G., Wright, C., Hollander, P., Roe, E., Jackson, A., Smiley, A., Burt, P., Estrada, L., Chionh, K., Ismail-Beigi, F., Falck-Ytter, C., Sayyed Kassem, L., Sood, A., Tiktin, M., Kulow, T., Newman, C., Stancil, K.A., Cramer, B., Iacoboni, J., Kononets, M.V., Sanders, C., Tucker, L., Werner, A., Maxwell, A., McPhee, G., Patel, C., Colosimo, L., Krol, A., Goland, R., Pring, J., Alfano, L., Kringas, P., Hausheer, C., Tejada, J., Gumpel, K., Kirpitch, A., Schneier, H., AbouAssi, H., Chatterjee, R., Feinglos, M.N., English Jones, J., Khan, S.A., Kimpel, J.B., Zimmer, R.P., Furst, M., Satterwhite, B.M., Thacker, C.R., Evans Kreider, K., Mariash, C.N., Mather, K.J., Ismail, H.M., Lteif, A., Mullen, M., Hamilton, T., Patel, N., Riera, G., Jackson, M., Pirics, V., Aguillar, D., Howard, D., Hurt, S., Bergenstal, R., Carlson, A., Martens, T., Johnson, M., Hill, R., Hyatt, J., Jensen, C., Madden, M., Martin, D., Willis, H., Konerza, W., Yang, S., Kleeberger, K., Passi, R., Fortmann, S., Herson, M., Mularski, K., Glauber, H., Prihoda, J., Ash, B., Carlson, C., Ramey, P.A., Schield, E., Torgrimson-Ojerio, B., Arnold, K., Kauffman, B., Panos, E., Sahnow, S., Bays, K., Berame, K., Cook, J., Ghioni, D., Gluth, J., Schell, K., Criscola, J., Friason, C., Jones, S., Nazarov, S., Rassouli, N., Puttnam, R., Ojoawo, B., Nelson, R., Curtis, M., Hollis, B., Sanders-Jones, C., Stokes, K., El-Haqq, Z., Kolli, A., Tran, T., Wexler, D., Larkin, M.E., Meigs, J., Chambers, B., Dushkin, A., Rocchio, G., Yepes, M., Steiner, B., Dulin, H., Cayford, M., Chu, K., DeManbey, A., Hillard, M., Martin, K., Thangthaeng, N., Gurry, L., Kochis, R., Raymond, E., Ripley, V., Stevens, C., Park, J., Aroda, V., Ghazi, A., Magee, M., Ressing, A., Loveland, A., Hamm, M., Hurtado, M., Kuhn, A., Leger, J., Manandhar, L., Mwicigi, F., Sanchez, O., Young, T., Garg, R., Lagari-Libhaber, V., Florez, H.J., Valencia, W.M., Marks, J., Casula, S., Oropesa-Gonzalez, L., Hue, L., Cuadot, A., Nieto-Martinez, R., Riccio Veliz, A.K., Gutt, M., Kendal, Y.J., Veciana, B., Ahmann, A., Aby-Daniel, D., Joarder, F., Morimoto, V., Sprague, C., Yamashita, D., Cady, N., Rivera-Eschright, N., Kirchhoff, P., Morales Gomez, B., Adducci, J., Goncharova, A., Hox, S.H., Petrovitch, H., Matwichyna, M., Jenkins, V., Broadwater, L., Ishii, R.R., Bermudez, N.O., Hsia, D.S., Cefalu, W.T., Greenway, F.L., Waguespack, C., King, E., Fry, G., Dragg, A., Gildersleeve, B., Arceneaux, J., Haynes, N., Thomassie, A., Pavlionis, M., Bourgeois, B., Hazlett, C., Henry, R., Boeder, S., Pettus, J., Diaz, E., Garcia-Acosta, D., Maggs, S., DeLue, C., Stallings, A., Castro, E., Hernandez, S., Krakoff, J., Curtis, J.M., Killean, T., Khalid, M., Joshevama, E., Diaz, E., Martin, D., Tsingine, K., Karshner, T., Albu, J., Pi-Sunyer, F.X., Frances, S., Maggio, C., Ellis, E., Bastawrose, J., Gong, X., Banerji, M.A., August, P., Lee, M., Lorber, D., Brown, N.M., Josephson, D.H., Thomas, L.L., Tsovian, M., Cherian, A., Jacobson, M.H., Mishko, M.M., Kirkman, M.S., Buse, J.B., Diner, J., Dostou, J., Machineni, S., Young, L., Bergamo, K., Goley, A., Kerr, J., Largay, J.F., Guarda, S., Cuffee, J., Culmer, D., Fraser, R., Almeida, H., Coffer, S., Debnam, E., Kiker, L., Morton, S., Josey, K., Fuller, G., Garvey, W.T., Cherrington, A.L., Dyer, D., Lawson, M.C.R., Griffith, O., Agne, A., McCullars, S., Cohen, R.M., Craig, J., Rogge, M.C., Burton, K., Kersey, K., Wilson, C., Lipp, S., Vonder Meulen, M.B., Adkins, C., Onadeko, T., Rasouli, N., Baker, C., Schroeder, E., Razzaghi, M., Lyon, C., Penaloza, R., Underkofler, C., Lorch, R., Douglass, S., Steiner, S., Sivitz, W.I., Cline, E., Knosp, L.K., McConnell, J., Lowe, T., Herman, W.H., Pop-Busui, R., Martin, C., Waltje, A., Katona, A., Goodhall, L., Eggleston, R., Kuo, S., Bojescu, S., Bule, S., Kessler, N., LaSalle, E., Whitley, K., Seaquist, E.R., Bantle, A., Harindhanavudhi, T., Kumar, A., Redmon, B., Bantle, J., Coe, M., Mech, M., Taddese, A., Lesne, L., Smith, S., Kuechenmeister, L., Shivaswamy, V., Burbach, S., Rodriguez, M.G., Seipel, K., Alfred, A., Morales, A.L., Eggert, J., Lord, G., Taylor, W., Tillson, R., Adolphe, A., Burge, M., Duran-Valdez, E., Martinez, J., Bancroft, A., Kunkel, S., Ali Jamaleddin Ahmad, F., Hernandez McGinnis, D., Pucchetti, B., Scripsick, E., Zamorano, A., DeFronzo, R.A., Cersosimo, E., Abdul-Ghani, M., Triplitt, C., Juarez, D., Mullen, M., Garza, R.I., Verastiqui, H., Wright, K., Puckett, C., Raskin, P., Rhee, C., Abraham, S., Jordan, L.F., Sao, S., Morton, L., Smith, O., Osornio Walker, L., Schnurr-Breen, L., Ayala, R., Kreymer, R.B., Sturgess, D., Kahn, S.E., Alarcon-Casas Wright, L., Boyko, E.J., Tsai, E.C., Trence, D.L., Trikudanathan, S., Fattaleh, B.N., Montgomery, B.K., Atkinson, K.M., Kozedub, A., Concepcion, T., Moak, C., Prikhodko, N., Rhothisen, S., Elasy, T.A., Martin, S., Shackelford, L., Goidel, R., Hinkle, N., Lovell, C., Myers, J., Lipps Hogan, J., McGill, J.B., Salam, M., Schweiger, T., Kissel, S., Recklein, C., Clifton, M.J., Tamborlane, W., Camp, A., Gulanski, B., Pham, K., Alguard, M., Gatcomb, P., Lessard, K., Perez, M., Iannone, L., Magenheimer, E., Montosa, A., Cefalu, W.T., Fradkin, J., Burch, H.B., Bremer, A.A., Nathan, D.M., Lachin, J.M., Buse, J.B., Kahn, S.E., Larkin, M.E., Tiktin, M., Wexler, D., Burch, H.B., Bremer, A.A., Lachin, J.M., Bebu, I., Butera, N., Buys, C.J., Fagan, A., Gao, Y., Gramzinski, M.R., Hall, S.D., Kazemi, E., Legowski, E., Liu, H., Suratt, C., Tripputi, M., Arey, A., Backman, M., Bethepu, J., Lund, C., Mangat Dhaliwal, P., McGee, P., Mesimer, E., Ngo, L., Steffes, M., Seegmiller, J., Saenger, A., Arends, V., Gabrielson, D., Conner, T., Warren, S., Day, J., Huminik, J., Soliman, E.Z., Zhang, Z.M., Campbell, C., Hu, J., Keasler, L., Hensley, S., Li, Y., Herman, W.H., Kuo, S., Martin, C., Waltje, A., Mihalcea, R., Min, D.J., Perez-Rosas, V., Prosser, L., Resnicow, K., Ye, W., Shao, H., Zhang, P., Luchsinger, J., Sanchez, D., Assuras, S., Groessl, E., Sakha, F., Chong, H., Hillery, N., Abdouch, I., Bahtiyar, G., Brantley, P., Broyles, F.E., Canaris, G., Copeland, P., Craine, J.J., Fein, W.L., Gliwa, A., Hope, L., Lee, M.S., Meiners, R., Meiners, V., O’Neal, H., Park, J.E., Sacerdote, A., Sledge Jr, E., Soni, L., Steppel-Reznik, J., and Turchin, A.

Published
2024
Full Text
View/download PDF

10. Expected and paradoxical effects of obesity on cancer treatment response

Author

Gallo, Marco, Adinolfi, Valerio, Barucca, Viola, Prinzi, Natalie, Renzelli, Valerio, Barrea, Luigi, Di Giacinto, Paola, Ruggeri, Rosaria Maddalena, Sesti, Franz, Arvat, Emanuela, Baldelli, Roberto, Arvat, Emanuela, Colao, Annamaria, Isidori, Andrea, Lenzi, Andrea, Baldell, Roberto, Albertelli, M., Attala, D., Bianchi, A., Di Sarno, A., Feola, T., Mazziotti, G., Nervo, A., Pozza, C., Puliani, G., Razzore, P., Ramponi, S., Ricciardi, S., Rizza, L., Rota, F., Sbardella, E., and Zatelli, M. C.

Published
2021
Full Text
View/download PDF

11. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

Author

Massironi, S., Campana, D., Pusceddu, S., Albertelli, M., Faggiano, A., Panzuto, F., Smiroldo, V., Andreasi, V., Rossi, R.E., Maggio, I., Torchio, M., Dotto, A., Modica, R., Rinzivillo, M., Carnaghi, C., Partelli, S., Fanetti, I., Lamberti, G., Corti, F., Ferone, D., Colao, A., Annibale, B., Invernizzi, P., and Falconi, M.

Published
2021
Full Text
View/download PDF

16. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

Author

Massironi, S, Campana, D, Pusceddu, S, Albertelli, M, Faggiano, A, Panzuto, F, Smiroldo, V, Andreasi, V, Rossi, R, Maggio, I, Torchio, M, Dotto, A, Modica, R, Rinzivillo, M, Carnaghi, C, Partelli, S, Fanetti, I, Lamberti, G, Corti, F, Ferone, D, Colao, A, Annibale, B, Invernizzi, P, Falconi, M, Massironi S., Campana D., Pusceddu S., Albertelli M., Faggiano A., Panzuto F., Smiroldo V., Andreasi V., Rossi R. E., Maggio I., Torchio M., Dotto A., Modica R., Rinzivillo M., Carnaghi C., Partelli S., Fanetti I., Lamberti G., Corti F., Ferone D., Colao A., Annibale B., Invernizzi P., Falconi M., Massironi, S, Campana, D, Pusceddu, S, Albertelli, M, Faggiano, A, Panzuto, F, Smiroldo, V, Andreasi, V, Rossi, R, Maggio, I, Torchio, M, Dotto, A, Modica, R, Rinzivillo, M, Carnaghi, C, Partelli, S, Fanetti, I, Lamberti, G, Corti, F, Ferone, D, Colao, A, Annibale, B, Invernizzi, P, Falconi, M, Massironi S., Campana D., Pusceddu S., Albertelli M., Faggiano A., Panzuto F., Smiroldo V., Andreasi V., Rossi R. E., Maggio I., Torchio M., Dotto A., Modica R., Rinzivillo M., Carnaghi C., Partelli S., Fanetti I., Lamberti G., Corti F., Ferone D., Colao A., Annibale B., Invernizzi P., and Falconi M.

Abstract

Background: Patients with sporadic neuroendocrine neoplasms may exhibit a higher risk of a second primary tumor than the general population. Aim: This study aimed to analyze the occurrence of second primary malignancies. Methods: A retrospective cohort of 2757 patients with sporadic lung and gastro-entero-pancreatic neuroendocrine neoplasms, managed at eight Italian tertiary referral Centers, was included. Results: Between 2000 and 2019, a second primary malignancy was observed in 271 (9.8%) neuroendocrine neoplasms patients with 32 developing a third tumor. There were 135 (49.8%) females and the median age was 64 years. The most frequent locations of the second tumors were breast (18.8%), prostate (12.5%), colon (9.6%), blood tumors (8.5%), and lung (7.7%). The second primary tumor was synchronous in 19.2% of cases, metachronous in 43.2%, and previous in 37.6%. As concerned the neuroendocrine neoplasms, the 5- and 10-year survival rates were 87.8% and 74.4%, respectively. PFS for patients with a second primary malignancy was shorter than for patients without a second primary malignancy. Death was mainly related to neuroendocrine neoplasms. Conclusion: In NEN patients the prevalence of second primary malignancies was not negligible, suggesting a possible neoplastic susceptibility. Overall survival was not affected by the occurrence of a second primary malignancy.

Published
2021

17. Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort

Author

Aroda, Vanita R., Krause-Steinrauf, Heidi, Kazemi, Erin J., Buse, John B., Gulanski, Barbara I., Florez, Hermes J., Ahmann, Andrew J., Loveland, Amy, Kuhn, Alexander, Lonier, Jacqueline Y., Wexler, Deborah J., Crandall, J.P., McKee, M.D., Behringer-Massera, S., Brown-Friday, J., Xhori, E., Ballentine-Cargill, K., Duran, S., Estrella, H., Gonzalez de la torre, S., Lukin, J., Phillips, L.S., Burgess, E., Olson, D., Rhee, M., Wilson, P., Raines, T.S., Boers, J., Costello, J., Maher-Albertelli, M., Mungara, R., Savoye, L., White, C.A., Gullett, C., Holloway, L., Morehead, F., Person, S., Sibymon, M., Tanukonda, S., Adams, C., Ross, A., Balasubramanyam, A., Gaba, R., Gonzalez Hattery, E., Ideozu, A., Jimenez, J., Montes, G., Wright, C., Hollander, P., Roe, E., Jackson, A., Smiley, A., Burt, P., Estrada, L., Chionh, K., Ismail-Beigi, F., Falck-Ytter, C., Sayyed Kassem, L., Sood, A., Tiktin, M., Kulow, T., Newman, C., Stancil, K.A., Cramer, B., Iacoboni, J., Kononets, M.V., Sanders, C., Tucker, L., Werner, A., Maxwell, A., McPhee, G., Patel, C., Colosimo, L., Krol, A., Goland, R., Pring, J., Alfano, L., Kringas, P., Hausheer, C., Tejada, J., Gumpel, K., Kirpitch, A., Schneier, H., Green, J.B., AbouAssi, H., Chatterjee, R., Feinglos, M.N., English Jones, J., Khan, S.A., Kimpel, J.B., Zimmer, R.P., Furst, M., Satterwhite, B.M., Thacker, C.R., Evans Kreider, K., Mariash, C.N., Mather, K.J., Ismail, H.M., Lteif, A., Mullen, M., Hamilton, T., Patel, N., Riera, G., Jackson, M., Pirics, V., Aguillar, D., Howard, D., Hurt, S., Bergenstal, R., Carlson, A., Martens, T., Johnson, M., Hill, R., Hyatt, J., Jensen, C., Madden, M., Martin, D., Willis, H., Konerza, W., Yang, S., Kleeberger, K., Passi, R., Fortmann, S., Herson, M., Mularski, K., Glauber, H., Prihoda, J., Ash, B., Carlson, C., Ramey, P.A., Schield, E., Torgrimson-Ojerio, B., Arnold, K., Kauffman, B., Panos, E., Sahnow, S., Bays, K., Berame, K., Cook, J., Ghioni, D., Gluth, J., Schell, K., Criscola, J., Friason, C., Jones, S., Nazarov, S., Barzilay, J., Rassouli, N., Puttnam, R., Ojoawo, B., Nelson, R., Curtis, M., Hollis, B., Sanders-Jones, C., Stokes, K., El-Haqq, Z., Kolli, A., Tran, T., Wexler, D., Larkin, M., Meigs, J., Chambers, B., Dushkin, A., Rocchio, G., Yepes, M., Steiner, B., Dulin, H., Cayford, M., Chu, K., DeManbey, A., Hillard, M., Martin, K., Thangthaeng, N., Gurry, L., Kochis, R., Raymond, E., Ripley, V., Stevens, C., Park, J., Aroda, V., Ghazi, A., Magee, M., Ressing, Ann, Loveland, A., Hamm, M., Hurtado, M., Kuhn, A., Leger, J., Manandhar, L., Sanchez, O., Young, T., Mofor, F., Garg, R., Lagari-Libhaber, V., Florez, H.J., Valencia, W.M., Marks, J., Casula, S., Oropesa-Gonzalez, L., Hue, L., Cuadot, A., Nieto-Martinez, R., Riccio Veliz, A.K., Gutt, M., Kendal, Y.J., Veciana, B., Ahmann, A., Aby-Daniel, D., Joarder, F., Morimoto, V., Sprague, C., Yamashita, D., Cady, N., Rivera-Eschright, N., Kirchhoff, P., Morales Gomez, B., Adducci, J., Goncharova, A., Hox, S.H., Petrovitch, H., Matwichyna, M., Jenkins, V., Broadwater, L., Ishii, R.R., Bermudez, N.O., Hsia, D.S., Cefalu, W.T., Greenway, F.L., Waguespack, C., King, E., Fry, G., Dragg, A., Gildersleeve, B., Arceneaux, J., Haynes, N., Thomassie, A., Pavlionis, M., Bourgeois, B., Hazlett, C., Mudaliar, S., Henry, R., Boeder, S., Pettus, J., Diaz, E., Garcia-Acosta, D., Maggs, S., DeLue, C., Stallings, A., Castro, E., Hernandez, S., Krakoff, J., Curtis, J.M., Killean, T., Khalid, M., Joshevama, E., Tsingine, K., Karshner, T., Albu, J., Pi-Sunyer, F.X., Frances, S., Maggio, C., Ellis, E., Bastawrose, J., Gong, X., Banerji, M.A., August, P., Lee, M., Lorber, D., Brown, N.M., Josephson, D.H., Thomas, L.L., Tsovian, M., Cherian, A., Jacobson, M.H., Mishko, M.M., Kirkman, M.S., Buse, J.B., Dostou, J., Machineni, S., Young, L., Bergamo, K., Goley, A., Kerr, J., Largay, J.F., Guarda, S., Cuffee, J., Culmer, D., Fraser, R., Almeida, H., Coffer, S., Debnam, E., Kiker, L., Morton, S., Josey, K., Fuller, G., Garvey, W.T., Cherrington, A.L., Dyer, D., Lawson, M.C.R., Griffith, O., Agne, A., McCullars, S., Cohen, R.M., Craig, J., Rogge, M.C., Burton, K., Kersey, K., Wilson, C., Lipp, S., Vonder Meulen, M.B., Adkins, C., Onadeko, T., Rasouli, N., Baker, C., Schroeder, E., Razzaghi, M., Lyon, C., Penaloza, R., Underkofler, C., Lorch, R., Douglass, S., Steiner, S., Sivitz, W.I., Cline, E., Knosp, L.K., McConnell, J., Lowe, T., Herman, W.H., Pop-Busui, R., Tan, M.H., Martin, C., Waltje, A., Katona, A., Goodhall, L., Eggleston, R., Kuo, S., Bojescu, S., Bule, S., Kessler, N., LaSalle, E., Whitley, K., Seaquist, E.R., Bantle, A., Harindhanavudhi, T., Kumar, A., Redmon, B., Bantle, J., Coe, M., Mech, M., Taddese, A., Lesne, L., Smith, S., Desouza, C., Kuechenmeister, L., Shivaswamy, V., Burbach, S., Rodriguez, M.G., Seipel, K., Alfred, A., Morales, A.L., Eggert, J., Lord, G., Taylor, W., Tillson, R., Schade, D.S., Adolphe, A., Burge, M., Duran-Valdez, E., Martinez, J., Bancroft, A., Kunkel, S., Ali Jamaleddin Ahmad, F., Hernandez McGinnis, D., Pucchetti, B., Scripsick, E., Zamorano, A., DeFronzo, R.A., Cersosimo, E., Abdul-Ghani, M., Triplitt, C., Juarez, D., Garza, R.I., Verastiqui, H., Wright, K., Puckett, C., Raskin, P., Rhee, C., Abraham, S., Jordan, L.F., Sao, S., Morton, L., Smith, O., Osornio Walker, L., Schnurr-Breen, L., Ayala, R., Kreymer, R.B., Sturgess, D., Utzschneider, K.M., Kahn, S.E., Alarcon-Casas, L., Wright, L., Boyko, E.J., Tsai, E.C., Trence, D.L., Trikudanathan, S., Fattaleh, B.N., Montgomery, B.K., Atkinson, K.M., Kozedub, A., Concepcion, T., Moak, C., Prikhodko, N., Rhothisen, S., Elasy, T.A., Martin, S., Shackelford, L., Goidel, R., Hinkle, N., Lovell, C., Myers, J., Lipps Hogan, J., McGill, J.B., Salam, M., Schweiger, T., Kissel, S., Recklein, C., Clifton, M.J., Tamborlane, W., Camp, A., Gulanski, B., Inzucchi, S.E., Pham, K., Alguard, M., Gatcomb, P., Lessard, K., Perez, M., Iannone, L., Magenheimer, E., Montosa, A., Burch, H.B., Bremer, A.A., Fradkin, J., Nathan, D.M., Lachin, J.M., Krause-Steinrauf, H., Younes, N., Backman, M., Bebu, I., Butera, N., Buys, C.J., Fagan Murphy, A., Gao, Y., Ghosh, A., Gramzinski, M.R., Kazemi, E., Hall, S.D., Legowski, E., Suratt, C., Tripputi, M., Arey, A., Bethepu, J., Lund, C., Mangat Dhaliwal, P., McGee, P., Mesimer, E., Ngo, L., Steffes, M., Seegmiller, J., Saenger, A., Arends, V., Gabrielson, D., Conner, T., Warren, S., Day, J., Huminik, J., Scrymgeour, A., Soliman, E.Z., Pokharel, Y., Zhang, Z.M., Campbell, C., Hu, J., Keasler, L., Hensley, S., Li, Y., Mihalcea, R., Min, D.J., Perez-Rosas, V., Prosser, L., Resnicow, K., Ye, W., Shao, H., Zhang, P., Luchsinger, J., Sanchez, D., Assuras, S., Groessl, E., Sakha, F., Chong, H., Hillery, N., Everett, B.M., Abdouch, I., Bahtiyar, G., Brantley, P., Broyles, F.E., Canaris, G., Copeland, P., Craine, J.J., Fein, W.L., Gliwa, A., Hope, L., Lee, M.S., Meiners, R., Meiners, V., O’Neal, H., Park, J.E., Sacerdote, A., Sledge, E., Soni, L., Steppel-Reznik, J., Turchin, A., Brooks-Worrell, B., Hampe, C.S., Newgard, C.B., Palmer, J.P., Shojaie, A., Higgins, J., Fischer, L., Golden, S., Gonzalez, J., Naik, A., Walker, E., Doner Lotenberg, L., Gallivan, J.M., Lim, J., and Tuncer, D.M.

Subjects
Clinical Care/Education/Nutrition/Psychosocial Research
Abstract

OBJECTIVE: Differences in type 2 diabetes phenotype by age are described, but it is not known whether these differences are seen in a more uniformly defined adult population at a common early stage of care. We sought to characterize age-related clinical and metabolic characteristics of adults with type 2 diabetes on metformin monotherapy, prior to treatment intensification. RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), participants were enrolled who had type 2 diabetes duration

Published
2022

20. Epidemiology of pancreatic neuroendocrine neoplasms. a gender perspective

Author

Muscogiuri, G., Altieri, B., Albertelli, M., Dotto, A., Modica, R., Barrea, L., Fanciulli, G., Feola, T., Baldelli, R., Ruggeri, R. M., Gallo, M., Guarnotta, V., Malandrino, P., Messina, E., Venneri, M. A., Giannetta, E., Ferone, D., Colao, A., Faggiano, A., Bottiglieri, F., Campione, S., de Cicco, F., Dicitore, A., Ferrau, F., Grillo, F., Grossrubatscher, E., Guadagno, E., Isidori, A. M., Lania, A., Lenzi, A., Calzo, F. L., Pes, L., Pizza, G., Pofi, R., Puliani, G., Rainone, C., Razzore, P., Rizza, L., Rubino, M., Sbardella, E., Sesti, F., Vitale, G., Zatelli, M. C., Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, Faggiano A, Muscogiuri, G., Altieri, B., Albertelli, M., Dotto, A., Modica, R., Barrea, L., Fanciulli, G., Feola, T., Baldelli, R., Ruggeri, R. M., Gallo, M., Guarnotta, V., Malandrino, P., Messina, E., Venneri, M. A., Giannetta, E., Ferone, D., Colao, A., Faggiano, A., Bottiglieri, F., Campione, S., de Cicco, F., Dicitore, A., Ferrau, F., Grillo, F., Grossrubatscher, E., Guadagno, E., Isidori, A. M., Lania, A., Lenzi, A., Calzo, F. L., Pes, L., Pizza, G., Pofi, R., Puliani, G., Rainone, C., Razzore, P., Rizza, L., Rubino, M., Sbardella, E., Sesti, F., Vitale, G., and Zatelli, M. C.

Subjects
Male, medicine.medical_specialty, Cardiovascular diseases, Epidemiology, Gender, Pancreatic neuroendocrine neoplasms, Sex, Type 2 diabetes, Female, Humans, Middle Aged, Pancreas, Retrospective Studies, Diabetes Mellitus, Type 2, Neuroendocrine Tumors, Pancreatic Neoplasms, Pancreatic neuroendocrine neoplasm, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Disease, Neuroendocrine tumors, Type 2 diabete, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Retrospective Studie, Internal medicine, Diabetes mellitus, medicine, gender, Pancrea, sex, business.industry, pancreatic neuroendocrine neoplasms, Retrospective cohort study, medicine.disease, Cardiovascular disease, cardiovascular diseases, Natural history, 030220 oncology & carcinogenesis, Pancreatitis, epidemiology, type 2 diabetes, business, Neuroendocrine Tumor, Human
Abstract

Purpose: Pancreatic neuroendocrine neoplasms (PNENs) are a group of clinically rare and heterogeneous tumors of the pancreas. Currently there are no studies investigating the gender difference in PNEN susceptibility. Thus, the purpose of this study was aimed at examining how gender shapes risk factors, clinicopathological features, and comorbidities in PNENs. Methods: The study design consisted of an Italian multicenter, retrospective study. The study included all consecutive patients with PNENs followed at the participating centers. Two hundred and twenty-nine patients (105 males,124 females, age 54 ± 0.98 years) with PNENs were enrolled at the participating centers. The clinicopathological features (age, gender, BMI, histology, tumor size, tumor grade, distant metastasis, hormonal function, and diagnostic circumstances), comorbidities (cardiovascular diseases (CVD), pancreatitis, type 2 diabetes (T2DM), and potential risk factors (smoking and drinking) were included in the analysis. Results: Females were slightly prevalent (54.15%). PNENs were diagnosed at younger age in females compared to males (p = 0.04). The prevalence of CVD was significantly higher in males than in females (p = 0.006). In the female group, the presence of T2DM was significantly associated with higher tumor grade (p = 0.04) and metastatic disease (p = 0.02). The proportion of smokers and alcohol drinkers was significantly higher in the male group (p < 0.001). No significant gender differences were detected regarding the other parameters included in the analysis. Conclusions: This study has identified gender differences of PNENs in terms of age at diagnosis, associated comorbidities, and potential risk factors. A gender-tailored approach could become a potential strategy to better understand the natural history of PNENs and improve the effectiveness of PNENs clinical management.

Published
2020

21. Open issues on G3 neuroendocrine neoplasms: back to the future

Author

Zatelli, Maria Chiara, Guadagno, Elia, Messina, Erika, Lo Calzo, Fabio, Faggiano, Antongiulio, Colao, Annamaria, Albertelli, M., Bianchi, A., CIRCELLI, MARIA TERESA, De Cicco, F., Dicitore, A., Di Dato, C., MOLFETTA, MARIA TERESA, Fanciulli, G., Ferraù, F., Gallo, M., GIANNETTA, MASSIMO, Grillo, F., Grossrubatscher, E., Guarnotta, V., Isidori, A. M., Kara, E., MALANDRINO, CORRADO, Modica, R., Muscogiuri, G., Pizza, G., Razzore, P., Rota, F., Rubino, M., Ruggeri, R. M., Sciammarella, C., Vitale, G., Zatelli, Maria Chiara, Guadagno, Elia, Messina, Erika, Lo Calzo, Fabio, Faggiano, Antongiulio, Colao, Annamaria, Albertelli, M., Bianchi, A., Circelli, MARIA TERESA, De Cicco, F., Dicitore, A., Di Dato, C., Molfetta, MARIA TERESA, Fanciulli, G., Ferraù, F., Gallo, M., Giannetta, Massimo, Grillo, F., Grossrubatscher, E., Guarnotta, V., Isidori, A. M., Kara, E., Malandrino, Corrado, Modica, R., Muscogiuri, G., Pizza, G., Razzore, P., Rota, F., Rubino, M., Ruggeri, R. M., Sciammarella, C., and Vitale, G.

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, Prognosi, Endocrinology, Diabetes and Metabolism, Neuroendocrine tumors, Diagnosis, G3, neuroendocrine tumors, prognosis, endocrinology, diabetes and metabolism, oncology, cancer research, NO, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Neuroendocrine tumor, medicine, Humans, Prognosis, Oncology, Intensive care medicine, business.industry, medicine.disease, Neuroendocrine Carcinomas, Diabetes and Metabolism, 030104 developmental biology, 030220 oncology & carcinogenesis, Neoplasm Grading, business, Diagnosi
Abstract

The recent recognition that grade 3 (G3) neuroendocrine neoplasms (NENs) can be divided into two different categories according to the histopathological differentiation, that is G3 neuroendocrine tumors (NETs) and G3 neuroendocrine carcinomas (NECs) has generated a lot of interest concerning not only the diagnosis, but also the differential management of such new group of NENs. However, several issues need to be fully clarified in order to put G3 NETs and G3 NECs in the right place. The aim of this review is to focus on those issues that are still undetermined starting from the current knowledge, evaluating the available evidence and the possible clinical implications.

Published
2018
Full Text
View/download PDF

22. Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks

Author

Fanciulli G., Di Molfetta S., Dotto A., Florio T., Feola T., Rubino M., de Cicco F., Colao A., Faggiano A., Albertelli M., Altieri B., Barrea L., Bottiglieri F., Campione S., Dicitore A., Ferone D., Ferrau F., Grossrubatscher E., Gallo M., Giannetta E., Grillo F., Guadagno E., Guarnotta V., Isidori A. M., Lania A., Lenzi A., Lo Calzo F., Malandrino P., Messina E., Modica R., Muscogiuri G., Pizza G., Pes L., Pofi R., Puliani G., Rainone C., Razzore P., Rizza L., Ruggieri R. M., Sbardella E., Sesti F., Venneri M. A., Vitale G., Zatelli M. C., Fanciulli G., Di Molfetta S., Dotto A., Florio T., Feola T., Rubino M., de Cicco F., Colao A., Faggiano A., Albertelli M., Altieri B., Barrea L., Bottiglieri F., Campione S., Dicitore A., Ferone D., Ferrau F., Grossrubatscher E., Gallo M., Giannetta E., Grillo F., Guadagno E., Guarnotta V., Isidori A.M., Lania A., Lenzi A., Lo Calzo F., Malandrino P., Messina E., Modica R., Muscogiuri G., Pizza G., Pes L., Pofi R., Puliani G., Rainone C., Razzore P., Rizza L., Ruggieri R.M., Sbardella E., Sesti F., Venneri M.A., Vitale G., Zatelli M.C., Fanciulli, G., Di Molfetta, S., Dotto, A., Florio, T., Feola, T., Rubino, M., de Cicco, F., Colao, A., Faggiano, A., Albertelli, M., Altieri, B., Barrea, L., Bottiglieri, F., Campione, S., Dicitore, A., Ferone, D., Ferrau, F., Grossrubatscher, E., Gallo, M., Giannetta, E., Grillo, F., Guadagno, E., Guarnotta, V., Isidori, A. M., Lania, A., Lenzi, A., Lo Calzo, F., Malandrino, P., Messina, E., Modica, R., Muscogiuri, G., Pizza, G., Pes, L., Pofi, R., Puliani, G., Rainone, C., Razzore, P., Rizza, L., Ruggieri, R. M., Sbardella, E., Sesti, F., Venneri, M. A., Vitale, G., and Zatelli, M. C.

Subjects
atezolizumab, avelumab, cemiplimab, durvalumab, immune checkpoint inhibitors, ipilimumab, nivolumab, paraganglioma, pembrolizumab, pheochromocytoma, lcsh:Medicine, Ipilimumab, Review, Immune checkpoint inhibitor, Pembrolizumab, Bioinformatics, Pheochromocytoma, Avelumab, 03 medical and health sciences, 0302 clinical medicine, Paraganglioma, Atezolizumab, Medicine, Ate-zolizumab, 030304 developmental biology, 0303 health sciences, business.industry, lcsh:R, General Medicine, medicine.disease, Clinical trial, 030220 oncology & carcinogenesis, Nivolumab, business, medicine.drug
Abstract

Pheochromocytoma and paraganglioma are neuroendocrine neoplasms, originating in the adrenal medulla and in parasympathetic and sympathetic autonomic nervous system ganglia, respectively. They usually present as localized tumours curable with surgery. However, these tumours may exhibit heterogeneous clinical course, ranging from no/minimal progression to aggressive (progressive/metastatic) behavior. For this setting of patients, current therapies are unsatisfactory. Immune checkpoint inhibitors have shown outstanding results for several types of solid cancers. We therefore aimed to summarize and discuss available data on efficacy and safety of current FDA-approved immune checkpoint inhibitors in patients with pheochromocytoma and paraganglioma. After an extensive search, we found 15 useful data sources (four full-published articles, four supplements of scientific journals, seven ongoing registered clinical trials). The data we detected, even with the limit of the small number of patients treated, make a great expectation on the therapeutic use of immune checkpoint inhibitors. Besides, the newly detected predictors of response will (hopefully) be of great helps in selecting the subset of patients that might benefit the most from this class of drugs. Finally, new trials are in the starting blocks, and they are expected to shed in the next future new light on a therapy, which is considered a milestone in oncology.

Published
2020
Full Text
View/download PDF

23. Expected and paradoxical effects of obesity on cancer treatment response

Author

Gallo, M, Adinolfi, V, Barucca, V, Prinzi, N, Renzelli, V, Barrea, L, Di Giacinto, P, Ruggeri, Rm, Sesti, F, Arvat, E, Baldelli, R, Eolo, Group, Colao, A, Isidori, A, Lenzi, A, Baldell, R, Albertelli, M, Attala, D, Bianchi, A, Di Sarno, A, Feola, T, Mazziotti, G, Nervo, A, Pozza, C, Puliani, G, Razzore, P, Ramponi, S, Ricciardi, S, Rizza, L, Rota, F, Sbardella, E, and Zatelli, Mc.

Subjects
Oncology, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, body mass index, cancer, cancer therapy, obesity, overweight, treatment outcome, Overweight, NO, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Risk Factors, Internal medicine, Diabetes mellitus, Neoplasms, Epidemiology, medicine, Humans, Cancer, Obesity, Body mass index, Cancer therapy, Treatment outcome, LS4_3, Risk factor, business.industry, medicine.disease, Prognosis, Cardiovascular Diseases, medicine.symptom, business, Obesity paradox
Abstract

Obesity, whose prevalence is pandemic and continuing to increase, is a major preventable and modifiable risk factor for diabetes and cardiovascular diseases, as well as for cancer. Furthermore, epidemiological studies have shown that obesity is a negative independent prognostic factor for several oncological outcomes, including overall and cancer-specific survival, for several site-specific cancers as well as for all cancers combined. Yet, a recently growing body of evidence suggests that sometimes overweight and obesity may associate with better outcomes, and that immunotherapy may show improved response among obese patients compared with patients with a normal weight. The so-called 'obesity paradox' has been reported in several advanced cancer as well as in other diseases, albeit the mechanisms behind this unexpected relationship are still not clear. Aim of this review is to explore the expected as well as the paradoxical relationship between obesity and cancer prognosis, with a particular emphasis on the effects of cancer therapies in obese people.

Published
2020

25. Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study

Author

Ruggeri, R. M., Altieri, B., Razzore, P., Retta, F., Sperti, E., Scotto, G., Brizzi, M. P., Zumstein, L., Pia, A., Lania, A., Lavezzi, E., Nappo, G., Laffi, A., Albertelli, M., Boschetti, M., Hasballa, I., Veresani, A., Prinzi, N., Pusceddu, S., Oldani, S., Nichetti, F., Modica, R., Minotta, R., Liccardi, A., Cannavale, G., Grossrubatscher, E. M., Tarsitano, M. G., Zamponi, V., Zatelli, M. C., Zanata, I., Mazzilli, R., Appetecchia, M., Davì, M. V., Guarnotta, V., Giannetta, E., La Salvia, A., Fanciulli, G., Malandrino, P., Isidori, A. M., Colao, A., and Faggiano, A.

Abstract

Background: The incidence of neuroendocrine neoplasm (NEN) and related carcinoid syndrome (CaS) has increased markedly in recent decades, and women appear to be more at risk than men. As per other tumors, gender may be relevant in influencing the clinical and prognostic characteristics of NEN-associated CS. However, specific data on carcinoid syndrome (CaS) are still lacking. Purpose: To evaluate gender differences in clinical presentation and outcome of CaS. Methods: Retrospective analysis of 144 CaS patients from 20 Italian high-volume centers was conducted. Clinical presentation, tumor characteristics, therapies, and outcomes (progression-free survival, PFS, overall survival, OS) were correlated to gender. Results: Ninety (62.5%) CaS patients were male. There was no gender difference in the site of primary tumor, tumor grade and clinical stage, as well as in treatments. Men were more frequently smokers (37.2%) and alcohol drinkers (17.8%) than women (9.5%, p= 0.002, and 3.7%, p= 0.004, respectively). Concerning clinical presentation, women showed higher median number of symptoms (p= 0.0007), more frequent abdominal pain, tachycardia, and psychiatric disorders than men (53.3% vs 70.4%, p= 0.044; 6.7% vs 31.5%, p= 0.001; 50.9% vs. 26.7%, p= 0.003, respectively). Lymph node metastases at diagnosis were more frequent in men than in women (80% vs 64.8%; p= 0.04), but no differences in terms of PFS (p= 0.51) and OS (p= 0.64) were found between gender. Conclusions: In this Italian cohort, CaS was slightly more frequent in males than females. Gender-related differences emerged in the clinical presentation of CaS, as well as gender-specific risk factors for CaS development. A gender-driven clinical management of these patients should be advisable.

Published
2023
Full Text
View/download PDF

27. T03.01.15 SECOND PRIMARY NEOPLASMS IN PATIENTS WITH GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NEN): DATA FROM A RETROSPECTIVE IT.A.NET STUDY

Author

Massironi, S., primary, Campana, D., additional, Pusceddu, S., additional, Albertelli, M., additional, Faggiano, A., additional, Panzuto, F., additional, Smiroldo, V., additional, Andreasi, V., additional, Rossi, R.E., additional, Maggio, I., additional, Torchio, M., additional, Ambrosetti, E., additional, Modica, R., additional, Rinzivillo, M., additional, Carnaghi, C., additional, Partelli, S., additional, Fanetti, I., additional, Lamberti, G., additional, Corti, F., additional, Dotto, A., additional, Colao, A., additional, Annibale, B., additional, Falconi, M., additional, and Invernizzi, P., additional

Published
2020
Full Text
View/download PDF

29. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

Author

Gallo M., Guarnotta V., De Cicco F., Rubino M., Faggiano A., Colao A., Albertelli M., Altieri B., Ambrosetti E., Bianchi A., Bottiglieri L., Campione S., Carra S., Di Dato C., DiMolfetta S., Di Sarno A., Fanciulli G., Ferone D., Ferrau F., Giannetta E., Grillo F., Grossrubatscher E. M., Guadagno E., Isidori A., Lo Calzo F., Malandrino P., Martini C., Messina E., Modica R., Muscogiuri G., Pizza G., Razzore P., Rizza L., Ruggeri R. M., Sciammarella C., Vitale G., Zatelli M. C., Gallo, M., Guarnotta, V., De Cicco, F., Rubino, M., Faggiano, A., Colao, A., Albertelli, M., Altieri, B., Ambrosetti, E., Bianchi, A., Bottiglieri, L., Campione, S., Carra, S., Di Dato, C., Dimolfetta, S., Di Sarno, A., Fanciulli, G., Ferone, D., Ferrau, F., Giannetta, E., Grillo, F., Grossrubatscher, E. M., Guadagno, E., Isidori, A., Lo Calzo, F., Malandrino, P., Martini, C., Messina, E., Modica, R., Muscogiuri, G., Pizza, G., Razzore, P., Rizza, L., Ruggeri, R. M., Sciammarella, C., Vitale, G., Zatelli, M. C., and Gallo Marco, Guarnotta Valentina, De Cicco Federica, Rubino Manila, Faggiano Antongiulio, Colao Annamaria

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, Avelumab, Skin Neoplasms, Prognosi, medicine.medical_treatment, Pembrolizumab, Immune checkpoint inhibitor, Cochrane Library, B7-H1 Antigen, Settore MED/13 - Endocrinologia, 03 medical and health sciences, Immune checkpoint inhibitors, 0302 clinical medicine, Merkel cell carcinoma, Neuroendocrine tumours, Neuroendocrine tumour, medicine, Animals, Humans, Skin Neoplasm, Intensive care medicine, business.industry, Animal, Antibodies, Monoclonal, General Medicine, Immunotherapy, medicine.disease, Prognosis, Immune checkpoint, Blockade, Clinical trial, Carcinoma, Merkel Cell, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Therapy, business, medicine.drug, Human
Abstract

Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC. Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic. Results: We performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies evaluating these issues: Are there any predictive criteria of response to immunotherapy? What is the correct place of immunotherapy in the treatment algorithm of MCC? What is the best choice after immunotherapy failure? What to do with patients for whom immunotherapy is not been feasible or contraindicated? How long should immunotherapy be prolonged, and what follow-up should be offered after complete response? Conclusion: The therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited.

Published
2019

30. A rare rarity: neuroendocrine tumor of the esophagus

Author

Giannetta, Elisa, Guarnotta, Valentina, Rota, Francesca, de Cicco, Federica, Grillo, Federica, Colao, Annamaria, Faggiano, Antongiulio, Albertelli, M., Bianchi, A., Circelli, L., Dicitore, A., Di Dato, C., Di Molfetta, S., Fanciulli, G., Ferrau, F., Gallo, M., Grossrubatscher, E., Guadagno, E., Lo Calzo, F., Kara, E., Malandrino, P., Messina, E., Modica, R., Muscogiuri, G., Pizza, G., Razzore, P., Rubino, M., Ruggeri, R. M., Sciammarella, C., Vitale, G., Zatelli, M. C., Giannetta, Elisa, Guarnotta, Valentina, Rota, Francesca, de Cicco, Federica, Grillo, Federica, Colao, Annamaria, Faggiano, Antongiulio, Albertelli, M., Bianchi, A., Circelli, L., Dicitore, A., Di Dato, C., Di Molfetta, S., Fanciulli, G., Ferrau, F., Gallo, M., Grossrubatscher, E., Guadagno, E., Lo Calzo, F., Kara, E., Malandrino, P., Messina, E., Modica, R., Muscogiuri, G., Pizza, G., Razzore, P., Rubino, M., Ruggeri, R. M., Sciammarella, C., Vitale, G., and Zatelli, M. C.

Subjects
0301 basic medicine, medicine.medical_specialty, Carcinoid tumors, esophageal neoplasms, Neuroendocrine tumors, Small-cell carcinoma, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, gastroenteropancreatic NET, Internal medicine, Epidemiology, medicine, risk factors, esophageal NEC, large cell esophageal NEN, MANEC, small cell carcinoma, delayed diagnosis, humans, neuroendocrine tumors, prognosis, rare diseases, Esophagus, Stage (cooking), business.industry, Large cell, Hematology, medicine.disease, Dysphagia, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, medicine.symptom, business
Abstract

Esophageal Neuroendocrine tumors (NETs) are rare, aggressive and lacking specific symptoms. This causes a diagnostic delay, worsening the prognosis. Numerous cases are reported in literature, without a consensus on the management. Our aim was to clarify epidemiology, clinical presentation, diagnostic, therapeutic management of esophageal NETs. Extensive literature search identified a total of 226 articles. One hundred twenty-five articles (n = 1676) met the inclusion criteria, showing that: the incidence of esophageal NET varies geographically; men (60–70 years) are more affected; smoking and alcohol abuse are the major risk factors; dysphagia, weight loss, appetite loss are the most common clinical features. The histotypes include high-grade small and large cell esophageal carcinomas and low-grade carcinoid tumors. Mixed neuroendocrine/non-neuroendocrine neoplasms are the most common. Often the diagnosis occurs randomly on endoscopic examination. Circulating markers, functional combined with conventional imaging contributes to the diagnosis and management. Treatment depends on type, grade and stage of the tumor.

Published
2019

32. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

Author

Massironi, S., Campana, D., Pusceddu c, S., Albertelli, M., Faggiano e, A., Panzuto f, F., Smiroldo g, V., Andreasi h, V., Rossi i, R. E., Maggio b, I., Torchio c, M., Dotto, A., Modica j, R., Rinzivillo f, M., Carnaghi k, C., Partelli h, S., Fanetti l, I., Lamberti b, G., Corti c, F., Ferone, D., Colao j, A., Annibale f, B., M, Invernizzi a, P., Falconi h, M., and ItaNet (Italian Association for Neuroendocrine Tumours) Study Group

Published
2020

33. GOSAFE - Geriatric Oncology Surgical Assessment and Functional rEcovery after Surgery: early analysis on 977 patients

Author

Montroni, I, Rostoft, S, Spinelli, A, Van Leeuwen, BL, Ercolani, G, Saur, NM, Jaklitsch, MT, Somasundar, PS, Carino, ND, Ghignone, F, Foca, F, Zingaretti, C, Audisio, RA, Ugolini, G, Garutti, A, Taffurelli, G, Zattoni, D, Tramelli, P, Sermonesi, G, Di Candido, F, Carvello, M, Sacchi, M, De Lucia, F, Foppa, C, Plas, M, Van der Wal-Huisman, H, Tauceri, F, Perenze, B, Di Pietrantonio, D, Mirarchi, M, Fejka, M, Bleier, JIS, Frain, L, Fox, SW, Cardin, K, De Leon, LE, Baltatzis, M, Chan, AKC, Siriwardena, AK, Vertogen, B, Nanni, O, Garulli, G, Alagna, V, Pirrera, B, Lucchi, A, Monari, F, Conti, L, Capelli, P, Romboli, A, Palmieri, G, Banchini, F, Marano, L, Spaziani, A, Castagnoli, G, Bartoli, A, Trompetto, M, Gallo, G, Luc, AR, Clerico, G, Sammarco, G, De Luca, R, Barile, G, Simone, M, Costanzi, A, Mari, G, Maggioni, D, Pellegrino, R, Riggio, V, Kenig, J, Szabat, K, Scabini, S, Pertile, D, Stratta, E, Massobrio, A, Soriero, D, Nesbakken, A, Lonn, M, Backe, IF, Ferrari, G, Mazzola, M, Alampi, BDA, Achilli, P, Sfondrini, S, Ioannidis, O, Loutzidou, L, Galanos-Demiris, K, Pellino, G, Balducci, G, Frezza, B, Lucarini, A, Santos, C, Cooper, L, Siam, B, Levy, Y, Brenner, B, Kashtan, H, Belgrano, V, De Cian, F, Palermo, B, Eggenhoffner, R, Albertelli, M, Sanchez-Guillen, L, Arroyo, A, Lopez-Rodriguez, F, Lario, S, Lillo, C, Wexner, SD, SIOG Surgical Task Force, and ESSO GOSAFE Study Grp

Subjects
MULTICENTER, CANCER
Abstract

Objective: Older patients with cancer value functional outcomes as much as survival, but surgical studies lack functional recovery (FR) data. The value of a standardized frailty assessment has been confirmed, yet it's infrequently utilized due to time restrictions into everyday practice. The multicenter GOSAFE study was designed to (1) evaluate the trajectory of patients' quality of life (QoL) after cancer surgery (2) assess baseline frailty indicators in unselected patients (3) clarify the most relevant tools in predicting FR and clinical outcomes. This is a report of the study design and baseline patient evaluations. Materials & Methods: GOSAFE prospectively collected a baseline multidimensional evaluation before major elective surgery in patients (70 years) from 26 international units. Short-/mid-/Iong-term surgical outcomes were recorded with QoL and FR data. Results: 1003 patients were enrolled in a 26-month span. Complete baseline data were available for 977(97.4%). Median age was 78 years (range 70-94); 52.8% males. 968(99%) lived at home, 51.6% without caregiver. 54.4% had 3 medications, 5.9% none. Patients were dependent (ADL < 5) in 7.9% of the cases. Frailty was either detected by G8 = 2(37.4%), TUG > 20 s (5.2%) or ASAIII-IV (48.8%). Major comorbidities (CACI > 6) were detected in 36%; 20.9% of patients had cognitive impairment according to Mini-Cog. Conclusion: The GOSAFE showed that frailty is frequent in older patients undergoing cancer surgery. QoL and FR, for the first time, are going to be primary outcomes of a real-life observational study. The crucial role of frailty assessment is going to be addressed in the ability to predict postoperative outcomes and to correlate with QoL and FR. (C) 2019 Elsevier Ltd. All rights reserved.

Published
2020

34. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours

Author

Zatelli, Maria Chiara, Fanciulli, Giuseppe, Malandrino, Pasqualino, NIKE GROUP: Albertelli M, Arvat E, Baldelli R, Berruti A, Bianchi A, Bodei L, Botti G, Corcione F, Daví MV, Delle Fave G, De Marinis L, Di Sarno A, Dicitore A, Fazio N, Ferolla P, Ferone D, Filice A, Gallo M, Giordano C, Giuffrida D, Guarnotta V, Lania A, Lastoria S, Logoluso F, Loli P, Manzoni M, Marchetti M, Martini C, Messina E, Modica R, Motta C, Papotti M, Partelli S, Persico G, Pia A, Piovesan A, Pontecorvi A, Razzore P, Rota F, Scavuzzo F, Sciammarella C, Vitale G., RAMUNDO, VALERIA, FAGGIANO, ANTONGIULIO, COLAO, ANNAMARIA, DE ROSA, GAETANO, Zatelli, M, Fanciulli, G, Malandrino, P, Ramundo, V, Faggiano, A, Colao, A, Giordano, C, Zatelli, Mc, Nike, Group, Partelli, S, Zatelli, Maria Chiara, Fanciulli, Giuseppe, Malandrino, Pasqualino, Ramundo, Valeria, Faggiano, Antongiulio, Colao, Annamaria, NIKE GROUP: Albertelli, M, Arvat, E, Baldelli, R, Berruti, A, Bianchi, A, Bodei, L, Botti, G, Corcione, F, Daví, Mv, Delle Fave, G, De Marinis, L, DE ROSA, Gaetano, Di Sarno, A, Dicitore, A, Fazio, N, Ferolla, P, Ferone, D, Filice, A, Gallo, M, Giuffrida, D, Guarnotta, V, Lania, A, Lastoria, S, Logoluso, F, Loli, P, Manzoni, M, Marchetti, M, Martini, C, Messina, E, Modica, R, Motta, C, Papotti, M, Persico, G, Pia, A, Piovesan, A, Pontecorvi, A, Razzore, P, Rota, F, Scavuzzo, F, Sciammarella, C, and Vitale, G.

Subjects
0301 basic medicine, Oncology, Cancer Research, mTOR inhibitor, Endocrinology, Diabetes and Metabolism, Neuroendocrine tumors, Antineoplastic Agent, 0302 clinical medicine, Endocrinology, Neuroendocrine tumours, neuroendocrine tumour, Treatment resistance, MTOR inhibitors, Tumor, Medical treatment, TOR Serine-Threonine Kinases, Discovery and development of mTOR inhibitors, Response to treatment, Patient management, Diabetes and Metabolism, Neuroendocrine Tumors, 030220 oncology & carcinogenesis, Neuroendocrine Tumor, Human, Predictors, Animals, Antineoplastic Agents, Biomarkers, Tumor, Diagnostic Imaging, Humans, Protein Kinase Inhibitors, medicine.medical_specialty, Protein Kinase Inhibitor, Early detection, predictor, Biology, NO, 03 medical and health sciences, mTOR inhibitors, neuroendocrine tumours, predictors, response to treatment, Internal medicine, medicine, mTOR inhibitors,neuroendocrine tumours,predictors,response to treatment, mTOR inhibitors, neuroendocrine tumours, predictors, response to treatment, Animal, medicine.disease, 030104 developmental biology, Immunology, Biomarkers, Resource utilization
Abstract

Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for therapeutic response are under intensive investigation, aiming at a tailored patient management and more appropriate resource utilization. This review summarizes the available data on the tissue, circulating and imaging markers that are potentially predictive of rapalog efficacy in NETs.

Published
2015
Full Text
View/download PDF

35. Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management

Author

Altieri B., Di Dato C., Martini C., Sciammarella C., DI SARNO, ALFONSO, Colao A., Faggiano A., Albertelli M., AMBROSETTI, ENRICO MARIO, Bianchi A., Bottiglieri F., Campione S., Carra S., De Cicco F., Di Molfetta S., Fanciulli G., Ferone D., Ferrau F., Gallo M., Giannetta E., Grillo F., Maria E. G., Guadagno E., Guarnotta V., Isidori A., Lo Calzo F., Malandrino P., Messina E., Modica R., Muscogiuri G., Pizza G., Razzore P., Rizza L., Rubino M., Ruggeri R. M., Vitale G., Zatelli M. C., Altieri, B., Di Dato, C., Martini, C., Sciammarella, C., DI SARNO, Alfonso, Colao, A., Faggiano, A., Albertelli, M., Ambrosetti, ENRICO MARIO, Bianchi, A., Bottiglieri, F., Campione, S., Carra, S., De Cicco, F., Di Molfetta, S., Fanciulli, G., Ferone, D., Ferrau, F., Gallo, M., Giannetta, E., Grillo, F., Maria, E. G., Guadagno, E., Guarnotta, V., Isidori, A., Lo Calzo, F., Malandrino, P., Messina, E., Modica, R., Muscogiuri, G., Pizza, G., Razzore, P., Rizza, L., Rubino, M., Ruggeri, R. M., Vitale, G., and Zatelli, M. C.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Prognosi, Skeletal-related event, education, Skeletal related events, 030209 endocrinology & metabolism, Review, lcsh:RC254-282, Pathogenesis, Bone metastases, Bone microenvironment, Denosumab, Epithelial-to-mesenchymal transition, Microrna, Neuroendocrine neoplasms, Prognosis, Skeletal-related events, Treatment, 03 medical and health sciences, 0302 clinical medicine, bone metastases, Quality of life, Internal medicine, medicine, neuroendocrine neoplasms, microRNA, treatment, medicine.diagnostic_test, business.industry, digestive, oral, and skin physiology, denosumab, Retrospective cohort study, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, skeletal-related events, Neuroendocrine neoplasm, Clinical Practice, Bone metastase, stomatognathic diseases, Positron emission tomography, Curative treatment, 030220 oncology & carcinogenesis, epithelial-to-mesenchymal transition, prognosis, business, bone microenvironment, medicine.drug
Abstract

Bone represents a common site of metastases for several solid tumors. However, the ability of neuroendocrine neoplasms (NENs) to localize to bone has always been considered a rare and late event. Thanks to the improvement of therapeutic options, which results in longer survival, and of imaging techniques, particularly after the introduction of positron emission tomography (PET) with gallium peptides, the diagnosis of bone metastases (BMs) in NENs is increasing. The onset of BMs can be associated with severe skeletal complications that impair the patient’s quality of life. Moreover, BMs negatively affect the prognosis of NEN patients, bringing out the lack of curative treatment options for advanced NENs. The current knowledge on BMs in gastro-entero-pancreatic (GEP) and bronchopulmonary (BP) NENs is still scant and is derived from a few retrospective studies and case reports. This review aims to perform a critical analysis of the evidence regarding the role of BMs in GEP- and BP-NENs, focusing on the molecular mechanisms underlining the development of BMs, as well as clinical presentation, diagnosis, and treatment of BMs, in an attempt to provide suggestions that can be used in clinical practice.

Published
2019
Full Text
View/download PDF

36. PRRT: identikit of the perfect patient.

Author

Albertelli, M., Dotto, A., Di Dato, C., Malandrino, P., Modica, R., Versari, A., Colao, A., Ferone, D., and Faggiano, A.

Abstract

Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated, and no optimal sequence has yet been standardized. Possible criteria to predict the response to PRRT in neuroendocrine tumors (NET) have been proposed. The aim of this review is to define the perfect identity of the eligible patient who can mostly benefit from this therapy. Possible predictive criteria which have been analysed were: primary tumor site, grading, tumor burden, FDG PET and 68Ga-PET uptake. Primary tumor site and 68Ga-PET uptake do not play a pivotal role in predicting the response, while tumor burden, FDG PET uptake and grading seem to represent predictive/prognostic factors for response to PRRT. The heterogeneity in trial designs, patient populations, type of radionuclides, previous therapies and measurement of outcomes, inevitably limits the strength of our conclusions, therefore care must be taken in applying these results to clinical practice. In conclusion, the perfect patient, selected by 68Ga-PET uptake, will likely have a relatively limited liver tumor burden, a ki67 index <20% and will respond to PRRT irrespective to primary tumor. Nevertheless, we have mostly prognostic than predictive factors to predict the efficacy of PRRT in individual patients, while a promising tool could be the NETest. However, to date, the identikit of the perfect patient for PRRT is a puzzle without some pieces and still we cannot disregard a multidisciplinary discussion of the individual case to select the patients who will mostly benefit from PRRT. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Safety of high doses of somatostatin analogs in well differentiated NENs in elderly

Author

Cani, M., primary, Incorvaia, L., additional, Fanale, D., additional, De Luca, I., additional, Gelsomino, F., additional, Ibrahim, T., additional, Pusceddu, S., additional, Riccardi, F., additional, Tafuto, S., additional, Lamberti, G., additional, Faggiano, A., additional, La salvia, A., additional, Albertelli, M., additional, Massironi, S., additional, Rinzivillo, M., additional, butturini, G., additional, Bazan, V., additional, Campana, D., additional, Russo, A., additional, and Badalamenti, G., additional

Published
2019
Full Text
View/download PDF

40. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.

Author

Singh S., Chan D.L., Ferone D., Albertelli M., Pavlakis N., Segelov E., Singh S., Chan D.L., Ferone D., Albertelli M., Pavlakis N., and Segelov E.

Abstract

Background/Purpose: Somatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting. Method(s): Eligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively. Result(s): Eighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0-14%). Rates of biochemical improvement (27-100%) and symptom improvement (23-100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues. Conclusion(s): The current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendoc

Published
2017

42. Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors

Author

Hofland, Leo, Vandamme, TAL, Albertelli, M, Ferone, D, and Internal Medicine

Subjects
hormones, hormone substitutes, and hormone antagonists
Abstract

Neuroendocrine tumors (NETs) produce various hormones and bioactive substances and are known to express a large variety of peptide hormone receptors. While these hormones and receptors play a role in the pathophysiology of this heterogeneous group of tumors, they also form an important target for treatment and diagnosis. One of the most well-known target receptors in NETs are somatostatin receptors. On the basis of the expression of functional somatostatin receptors on the cell surface of NET cells, somatostatin analogs have already been used for decades to control symptoms related to hormonal overproduction in patients with NETs. Recent placebo-controlled studies have also demonstrated a significant antitumor activity, both in functioning and nonfunctioning NETs. Moreover, other peptide hormone receptors (e. g. receptors for GLP-1, CCK, GRP, secretin and dopamine) can be expressed at a high density in NETs. As such, these classes of receptors may also form potential targets for diagnosis and treatment. Finally, in recent years novel biotherapies targeting several growth factor systems have been introduced in the treatment of patients with NETs and are being explored for their efficacy in this setting, either as monotherapy or in combination treatment. This chapter aims to give an overview on the above topic. (C) 2015 S. Karger AG, Basel

Published
2015

43. Appendiceal neuroendocrine tumors: a large multicentre Italian series. Preliminary result

Author

Lamberti, G., primary, Rossi, G., additional, Grillo, F., additional, Spada, F., additional, Pusceddu, S., additional, Rinzivillo, M., additional, Massironi, S., additional, Tafuto, S., additional, Faggiano, A., additional, Antonuzzo, L., additional, Luppi, G., additional, Albertelli, M., additional, Fazio, N., additional, Vernieri, C., additional, Delle Fave, G., additional, Brighi, N., additional, Ferone, D., additional, and Campana, D., additional

Published
2016
Full Text
View/download PDF

44. Optimization of flow reserve measurement using SPECT technology to evaluate the determinants of coronary microvascular dysfunction in diabetes

Author

Marini C. 1, Bezante G. 2, Gandolfo P. 3, Modonesi E. 2, Morbelli S.D. 3, Depascale A. 4, Rollando D. 2, Maggi D. 4, Albertelli M. 4, Armonino R. 3, Balbi M. 2, Brunelli C. 2, Cordera R. 4, Sambuceti G. 3, and 5

Subjects
Transthoracic contrast echo Doppler, Myocardial perfusion reserve, Type 2 diabetes mellitus, GatedSPECT
Abstract

PURPOSE: The aim of this study was to validate a new method to measure regional myocardial perfusion reserve (MPR) with technetium-labelled tracers in patients with type 2 diabetes mellitus (DM2). METHODS: A total of 40 consecutive DM2 patients without history of coronary artery disease (CAD) and 7 control subjects were recruited. Dipyridamole myocardial blood flow index (MBF) was assessed by measuring first transit counts in the pulmonary artery and myocardial count rate from gated SPECT images using (99m)Tc-labelled tracers. The corresponding MBF index was estimated 2 h later according to the same procedure. Regional myocardial perfusion reserve (MPR) was defined as the ratio between dipyridamole and baseline MBF using a 17-segment left ventricular (LV) model. Coronary flow reserve (CFR) was estimated by transthoracic contrast echo Doppler monitoring of flow velocity in the left anterior descending coronary artery (LAD) during the same session. RESULTS: Estimated MPR was higher in control subjects than in patients (3.36 +/- 0.66 vs 1.91 +/- 0.61, respectively, p < 0.01). In patients, LAD CFR and LAD MPR were 2.01 +/- 0.78 vs 1.93 +/- 0.63, respectively (p = ns). The agreement between the two techniques was documented by their close correlation (r = 0.92, p < 0.001) and confirmed by the Bland-Altman analysis. Reversible perfusion defects occurred in 13 patients (32%) who showed similar MPR values as the remaining 27 (2.10 +/- 0.71 vs 1.83 +/- 0.71, respectively, p = ns). Finally, MPR was closely correlated with age (r = -0.50, p < 0.01) and time elapsed from the diagnosis of DM2 (r = -0.51, p < 0.01). CONCLUSION: LV regional MPR can be accurately estimated with the broadly available single photon technology. Application of this method to DM2 patients documents the presence of a microvascular dysfunction homogeneously distributed throughout the LV walls and most frequently not associated with reversible perfusion defects.

Published
2010

45. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am

Author

Ferone, D., Arvigo, M., Semino, C., Jaquet, P., Saveanu, Alexandru, Taylor, J.E., Moreau, J.P., Culler, M.D., Albertelli, M., Minuto, F., Barreca, A., Gautron, Conception, Interactions cellulaires neuroendocriniennes (ICN), and Université de la Méditerranée - Aix-Marseille 2-Centre National de la Recherche Scientifique (CNRS)

Published
2005

48. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures

Author

Mohamed, A., primary, Blanchard, M.-P., additional, Albertelli, M., additional, Barbieri, F., additional, Brue, T., additional, Niccoli, P., additional, Delpero, J.-R., additional, Monges, G., additional, Garcia, S., additional, Ferone, D., additional, Florio, T., additional, Enjalbert, A., additional, Moutardier, V., additional, Schonbrunn, A., additional, Gerard, C., additional, Barlier, A., additional, and Saveanu, A., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results